Memantine Vipharm

Memantine, the active ingredient in Memantine Vipharm, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of Alzheimer’s disease in adults, helping to improve cognition and functional abilities by modulating glutamatergic neurotransmission.

GNH USA supplies Memantine Vipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards, provides reliable global distribution, and ensures that each batch meets regulatory requirements for safety and efficacy.

Memantine is employed in the management of neurodegenerative disorders that involve excessive glutamate activity, particularly Alzheimer’s disease.

Alzheimer's disease: improves cognition, memory, and daily functional abilities in patients with mild to moderate disease, and may delay symptom progression when used as part of a comprehensive therapeutic regimen.

Memantine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue - Nausea - Confusion

Serious or Rare Side Effects: - Seizures - Hallucinations or psychosis - Severe hypertension - Allergic skin reactions (rash, Stevens‑Johnson syndrome) - Hepatic dysfunction - Cardiac arrhythmia

When prescribing Memantine, clinicians should consider several safety factors. - Renal impairment: adjust dose or monitor renal function closely. - History of seizures: monitor for increased seizure activity. - Concomitant NMDA antagonists: avoid additive neurotoxicity. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Ketamine: additive NMDA antagonism leading to excessive CNS depression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may reduce cognitive benefit. - Diuretics: can raise plasma memantine concentrations. - CNS depressants (e.g., benzodiazepines): may enhance sedation and dizziness. - Proton pump inhibitors: may modestly increase memantine exposure. - Antihypertensives: monitor blood pressure for additive effects.